Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Chin Med Sci J ; 33(3): 174-182, 2018 Sep 20.
Article in English | MEDLINE | ID: mdl-30266108

ABSTRACT

Programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) is a significant immune checkpoint, and the dysfunction of this axis contributes to tumor metastasis and immune escape. PI3K/Akt/mTOR and MAPK signal network induces PD-1/PD-L1 expression and facilitates tumor progression. Transcriptional factors such as hypoxia induced factors, PTEN, p53, CDK5, BRD4, STAT modulate PD-1/PD-L1 expression. PD-1/PD-L1 level is also regulated via epigenetic and post-translational manner. The underlying mechanisms mentioned above may provide potential targets for tumor treatment. At present, the combination therapy of PD-1/PD-L1 monoclonal antibodies plus small molecular inhibitors has achieved good outcomes in tumor treatment.


Subject(s)
B7-H1 Antigen/genetics , Immunotherapy , Neoplasms/immunology , Neoplasms/therapy , Programmed Cell Death 1 Receptor/genetics , Animals , B7-H1 Antigen/metabolism , Epigenesis, Genetic , Humans , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...